Terumo aims to expand production capacity and strengthen its global responsiveness by utilizing the newly acquired DP plant as its first overseas CDMO production base. This will accelerate the global expansion of the CDMO business.
The DP plant acquired from WuXi Biologics is equipped with state-of-the-art facilities compliant with GMP*3 standards. It is also staffed with highly skilled personnel, production know-how, and a proven track record. Leveraging these assets, Terumo will commence the development and production of prefilled syringe products and vial products at the plant. This will enable the company to address the growing demand for CDMO services, particularly in Europe and the United States, driven by the rapid growth of biopharmaceuticals.
Currently, Terumo has CDMO production bases at the Kofu, Fujinomiya, and Yamaguchi factories. The company has continuously enhanced its production capacity in line with the expansion of the CDMO business. In December 2023, Terumo expanded the CDMO production capabilities by expanding the production lines at the Yamaguchi factory. Additionally, the company is in the process of installing new production lines in the Kofu factory’s newly constructed building, which is currently under construction and scheduled for completion in fiscal 2025. By establishing a new CDMO production base in Europe, Terumo aims to strengthen its global operations to meet the growing needs of pharmaceutical companies both domestically and internationally.
"The acquisition of the drug product plant is a pivotal step in enhancing the competitiveness of our CDMO business, and we are thrilled to have reached an agreement with WuXi Biologics,” said Hikaru Samejima, Chief Executive Officer, Terumo Corporation. “By integrating the high-quality and stable production operations of the Leverkusen plant and the exceptional talent supporting it with Terumo, we are confident that we will significantly elevate the global responsiveness of our CDMO business."
Overview of the drug product plant to be acquired from WuXi BiologicsLocation Leverkusen, North Rhine-Westphalia, Germany
Site area of the plant 13,000㎡
Description of business CDMO business for vial products (as of May 2025)
Number of employees Approximately 150
*1 Converted at an exchange rate of 1 Euro to 164 yen
*2 Contract Development and Manufacturing Organization
*3 Good Manufacturing Practice
(Reference) Terumo’s CDMO businessThrough partnerships, Terumo's CDMO business supports pharmaceutical companies in the design, manufacturing and regulatory approval processes of combination products. Since biopharmaceuticals are mainly administered as injectables, the importance of developing appropriate containers and delivery devices tailored to the characteristics of the drugs, as well as technologies for aseptic filling of drugs, is increasing. Leveraging its unique technologies and expertise cultivated through prefilled syringe products, Terumo develops and provides delivery devices such as injection needles and syringe pumps. These devices globally support pharmaceutical companies in resolving drug-related challenges and enhancing the value of pharmaceuticals.
